Abstract:

Acute myeloid leukemia (AML) is a neoplastic disease of the hemopoetic root cell. The incidence of AML increases with age and is more detected in men than in women. Remission induction chemotherapy is the first stage of AML treatment. In standard induction therapy, a combination of sitarabin and antrasyklin is used. In this study, our goal is to determine whether different types of anthrasicillins in the AML remission induction chemotherapy make a difference in receiving remission and in the need for support treatment. For this, from January 2004 to December 2009 a total of 6 years of treatment in the Hematology Clinic of the University Hospital of Uludağ, with the diagnosis of 3+7 remission induction chemotherapy, from 123 incidents to full remission, 96 incidents were recurrently assessed. Of the 96 patients received, 44 (45.8%) were women and 52 (54.2%) were men. The most common subtypes of FAB were: M2 (29.3%), M3 (15.4%) and M4 (13.0%). The number of patients and the types of anthracyclins they received were: administrubisin (72 patients, 75%), docsorubisin (12 patients, 12.5%), daunorubisin (9 patients, 9.4%), or mitoxantron (3 patients, 3.1%). If the period of the neutropeni was in the group of dosorubis (the average of 16.5 days; December 5-23). The number of days we used antibiotics was in the area group of the administration (the average 27 days; December 10-45). The average monitoring period of our patients was 25.7 months, the average 15 months (2-70 months). It was found that 33 of these patients (34.4 percent) were missing in their follow-up. 21 patients found early nurses (21.9 percent) (<12 months) and 12 patients late nurses (12.5 percent) (>12 months). 54 of our patients (56.2%) were alive and 42 (43.8%) died. As a result, inductive chemotherapies containing different antrasicillins may show similar characteristics in terms of therapeutic success, while support therapy needs may differ.

Keywords: